Jason Douglas Wilson Sells 10,000 Shares of Reata Pharmaceuticals Inc (NASDAQ:RETA) Stock

Reata Pharmaceuticals Inc (NASDAQ:RETA) VP Jason Douglas Wilson sold 10,000 shares of the business’s stock in a transaction dated Thursday, October 17th. The stock was sold at an average price of $170.00, for a total transaction of $1,700,000.00. Following the sale, the vice president now directly owns 17,350 shares in the company, valued at approximately $2,949,500. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

Jason Douglas Wilson also recently made the following trade(s):

  • On Monday, October 14th, Jason Douglas Wilson sold 15,000 shares of Reata Pharmaceuticals stock. The stock was sold at an average price of $100.00, for a total transaction of $1,500,000.00.
  • On Thursday, August 15th, Jason Douglas Wilson sold 4,000 shares of Reata Pharmaceuticals stock. The stock was sold at an average price of $72.68, for a total transaction of $290,720.00.

NASDAQ:RETA opened at $180.18 on Wednesday. Reata Pharmaceuticals Inc has a one year low of $47.50 and a one year high of $189.39. The company’s 50-day simple moving average is $100.67 and its 200 day simple moving average is $88.98. The firm has a market capitalization of $5.57 billion, a P/E ratio of -62.78 and a beta of 2.40.

Reata Pharmaceuticals (NASDAQ:RETA) last issued its earnings results on Thursday, August 8th. The company reported ($1.14) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.12) by ($0.02). The firm had revenue of $7.83 million during the quarter, compared to the consensus estimate of $7.76 million. Reata Pharmaceuticals had a negative return on equity of 3,282.73% and a negative net margin of 410.38%. As a group, analysts anticipate that Reata Pharmaceuticals Inc will post -5.33 earnings per share for the current year.

RETA has been the topic of several research reports. National Securities initiated coverage on shares of Reata Pharmaceuticals in a research note on Thursday, September 26th. They set a “buy” rating and a $130.00 price objective on the stock. Cantor Fitzgerald boosted their price objective on shares of Reata Pharmaceuticals from $125.00 to $180.00 and gave the stock an “overweight” rating in a research note on Tuesday, October 15th. Robert W. Baird reissued an “outperform” rating and set a $162.00 price objective (up previously from $105.00) on shares of Reata Pharmaceuticals in a research note on Tuesday, October 15th. Jefferies Financial Group boosted their price objective on shares of Reata Pharmaceuticals from $128.00 to $254.00 and gave the stock a “buy” rating in a research note on Tuesday, October 15th. Finally, Citigroup boosted their price objective on shares of Reata Pharmaceuticals from $194.00 to $241.00 and gave the stock a “buy” rating in a research note on Tuesday, October 15th. One analyst has rated the stock with a sell rating, one has given a hold rating and nine have issued a buy rating to the stock. Reata Pharmaceuticals presently has a consensus rating of “Buy” and an average target price of $205.75.

Several hedge funds and other institutional investors have recently modified their holdings of the company. Zurcher Kantonalbank Zurich Cantonalbank lifted its stake in shares of Reata Pharmaceuticals by 25.1% in the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 1,240 shares of the company’s stock worth $100,000 after buying an additional 249 shares in the last quarter. Nisa Investment Advisors LLC lifted its stake in shares of Reata Pharmaceuticals by 853.3% in the third quarter. Nisa Investment Advisors LLC now owns 1,430 shares of the company’s stock worth $115,000 after buying an additional 1,280 shares in the last quarter. Osborn Williams & Donohoe LLC lifted its stake in shares of Reata Pharmaceuticals by 3.1% in the third quarter. Osborn Williams & Donohoe LLC now owns 80,908 shares of the company’s stock worth $6,496,000 after buying an additional 2,450 shares in the last quarter. Mackenzie Financial Corp bought a new position in shares of Reata Pharmaceuticals in the second quarter worth approximately $693,000. Finally, Eaton Vance Management bought a new position in shares of Reata Pharmaceuticals in the second quarter worth approximately $1,033,000. Hedge funds and other institutional investors own 58.51% of the company’s stock.

Reata Pharmaceuticals Company Profile

Reata Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, develops novel therapeutics for patients with serious or life-threatening diseases by targeting molecular pathways that regulate cellular metabolism and inflammation. The company is developing Phase III clinical trial programs, including bardoxolone methyl (Bard) for the treatment of patients with chronic kidney disease caused by Alport syndrome, as well as for a form of pulmonary arterial hypertension associated with connective tissue disease; and omaveloxolone that is Phase II clinical trial for the treatment of patients with Friedreich's ataxia It is also developing RTA 901, which completed Phase 1 clinical trials for the treatment of orphan neurological indications; and RORgT Inhibitors that are in the preclinical development phase for the potential treatment of a range of autoimmune, inflammatory, and fibrotic diseases.

Further Reading: What are the economic characteristics of a bear market?

Insider Buying and Selling by Quarter for Reata Pharmaceuticals (NASDAQ:RETA)

Receive News & Ratings for Reata Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Reata Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.